Personalis

Personalis Financial Leverage

The Financial Leverage (Equity Multiplier) of Personalis (PSNL) as of Oct 28, 2026 is 1.28. In the previous year, Financial Leverage (Equity Multiplier) was 1.33 — a change of -3.92% (lower).

Financial Leverage

1.28

YoY

-3.92%

Last updated:

Financial Leverage (Equity Multiplier) of Personalis is 2025 1.28 . Financial Leverage (Equity Multiplier) of Personalis was 2024 1.33 . It decreases by -3.92% lower compared to the previous year.

The Personalis Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
-0.39 USD
Jan 1, 2019
1.47 USD
Jan 1, 2020
1.26 USD
Jan 1, 2021
1.28 USD
Jan 1, 2022
1.34 USD
Jan 1, 2023
1.74 USD
Jan 1, 2024
1.33 USD
Jan 1, 2025
1.28 USD
The Personalis Financial Leverage history
YEARFinancial LeverageYoY
1.28-3.92%
1.33-23.42%
1.74+29.60%
1.34+5.00%
1.28+1.75%
1.26-14.81%
1.47-476.40%
-0.39+8.07%
-0.36—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Personalis Stock analysis

What does Personalis do? Personalis Inc is a diagnostic company specializing in the development of tests for personalized medicine. The company was founded in 2011 by Dr. Richard Chen and Dr. Erin Newburn and is headquartered in Menlo Park, California. They initially focused on developing genomic tools for cancer diagnosis and treatment but have expanded their offerings to include tests for rare genetic diseases, immunotherapies, and precision oncology drugs. They work closely with pharmaceutical and biotechnology companies as well as academics to develop innovative therapeutic approaches. Their business model is based on making genomics biology usable for personalized medicine and clinical research. They have a wide portfolio of genomic-based solutions for personalized medicine, including tests for tumor mutations, tumor-specific neoantigens, rare genetic diseases, and personalized immunotherapy. They also offer customized genomic solutions for pharmaceutical and biotechnology companies. Personalis Inc aims to establish personalized medicine quickly and effectively to provide the best possible outcome for patients. Personalis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Personalis stock

Financial Leverage (Equity Multiplier) of Personalis is 1.28 in 2025.

Financial Leverage (Equity Multiplier) of Personalis changed from 1.33 to 1.28, representing a -3.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Personalis since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Personalis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Personalis

All Key Metrics — Personalis